BUSINESS FDA says manufacturing delays are constraining EpiPen supply

BUSINESS

FDA says manufacturing delays are constraining EpiPen supply

Reuters

07:15, May 10, 2018

image.png

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, US August 24, 2016 (Photo: Reuters)

The US Food and Drug Administration added Mylan NV’s (MYL.O) EpiPen to its list of drugs in shortage on Wednesday, saying that manufacturing delays were creating intermittent supply constraints of the emergency allergy treatment.The FDA said the status of Epipen, a lower dose version called EpiPen Jr, and Mylan’s own generic versions of those products were currently available, but that “supply levels may vary across wholesalers and pharmacies.”

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue